LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Giant Cell Tumors of Bone With Pulmonary Metastasis: 145

Photo by impulsq from unsplash

In young patients, 81%, 38%, 87%, 7%, 40%, and 67% of tumors were positive for CK7, CK20, CK19, NCAM, N-Cadherin, S100P, compared to 95%, 32%, 95%, 0%, 52%, and 38%… Click to show full abstract

In young patients, 81%, 38%, 87%, 7%, 40%, and 67% of tumors were positive for CK7, CK20, CK19, NCAM, N-Cadherin, S100P, compared to 95%, 32%, 95%, 0%, 52%, and 38% in the control group, respectively. Diffuse strong expression of p53 was observed in 33% of tumors of the young (vs 52% in control group). All tumors had intact expression of mismatch repair proteins. Mean follow-up time was 2.8 years (range 0.25–11 years). Fourteen (70%) patients died of disease, and the five-year survival rate was 25%. Conclusion: Cholangiocarcinoma of the young is highly aggressive, most commonly presenting at advanced stage and with high histologic grade, and is hence associated with poor survival. It is more commonly intrahepatic than cholangiocarcinoma in older adults, but is morphologically and immunohistochemically similar to it, except for increased expression of S100P and decreased expression of p53.

Keywords: giant cell; metastasis 145; tumors bone; bone pulmonary; pulmonary metastasis; cell tumors

Journal Title: American Journal of Clinical Pathology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.